Daiichi Sankyo has announced plans to split and transfer its inventories to Alfresa Pharma, along with Japanese manufacturing and sales approvals for 41 long-listed products.
All the products are currently manufactured and sold in the country by Daiichi Sankyo’s Espha unit. The decision to transfer the assets follows an evaluation of Daiichi Sankyo’s business optimisation.
Effective from March next year, the transfer will involve a payment of JPY8.42bn ($75.82m) from Alfresa Pharma to Daiichi Sankyo.
The 41 products involved in the deal are said to have generated JPY9.16bn ($82.49) in revenues during the fiscal year that ended on 31 March 2018.
The company has also signed an exclusive worldwide licensing agreement with immuno-oncology firm Glycotope for the development of an antibody drug conjugate (ADC).
Under the terms of the agreement, Daiichi Sankyo will combine its ADC technology with Glycotope’s investigational TA-MUC1 antibody called gatipotuzumab.
Daiichi Sankyo ADC Task Force vice-president and head Tom Held said: “With the licensing of gatipotuzumab with the intention of developing an ADC, we now have seven novel ADCs in development, which demonstrate our commitment to maximising the potential of our proprietary ADC payload and linker technology to help address the unmet needs of patients with cancer worldwide.”
The company will hold the exclusive rights for the development and commercialisation of gatipotuzumab ADC, while Glycotope will receive an upfront payment, potential clinical, regulatory and sales milestone payments, and royalties on global net sales.
Glycotope managing director Henner Kollenberg said: “Our world-leading glyco-biology expertise has allowed us to create a novel anti-TA-MUC1 monoclonal antibody with carbohydrate mediated tumour-specificity and high affinity binding.
“We look forward to continuing to work with Daiichi Sankyo on this ADC programme and on the further development of gatipotuzumab in other formats.”
Financial terms of the agreement have not been disclosed.